UCLA team developing one-time, inhalable CF gene-editing treatment
Researchers at the University of California, Los Angeles (UCLA) are developing a gene-editing therapy — designed to be delivered as a one-time inhalable treatment — that aims to correct the underlying mutations that cause cystic fibrosis (CF). The team is using tiny fat-based particles to deliver the gene-editing machinery…